Company DBV Technologies

DBV

FR0010417345

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for DBV Technologies

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:06 2024-05-28 am EDT			After market 03:59:59 pm
1.22 ^EUR	-1.61%		1.221	+0.08%

May. 23	Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	MT
May. 21	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	MT

DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.

Number of employees: 105

EUR in Million	2022	Weight	2023	Weight	Delta
Epicutaneous Immunotherapy Products 100.0 %	5	100.0 %	15	100.0 %	+215.64%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	5	100.0 %	15	100.0 %	+215.64%

Managers	Title	Age	Since
Daniel Tassé CEO	Chief Executive Officer	64	18-11-28
Virginie Simone Jeanine Verrechia DFI	Director of Finance/CFO	54	Nov. 05
Pharis Mohideen CTO	Chief Tech/Sci/R&D Officer	59	19-07-21
Pascale Ehouarn CTO	Chief Tech/Sci/R&D Officer	-	05-12-31
Katie Matthews IRC	Investor Relations Contact	-	-
Pascal Wotling PRN	Corporate Officer/Principal	-	20-03-31
Michele F. Robertson LAW	General Counsel	-	21-02-21
Caroline Daniere HRO	Human Resources Officer	50	19-09-01

Members of the board	Title	Age	Since
Timothy Morris BRD	Director/Board Member	61	21-02-28
Michel de Rosen CHM	Chairman	73	18-06-21
Don Soland BRD	Director/Board Member	65	15-03-05
Michael Goller BRD	Director/Board Member	49	15-10-20
Daniel Tassé CEO	Chief Executive Officer	64	18-11-28
Maïlys Ferrère BRD	Director/Board Member	60	16-06-20
Danièle Guyot-Caparros BRD	Director/Board Member	64	22-10-02
Julie O'Neill BRD	Director/Board Member	58	17-06-14
Ravi Rao BRD	Director/Board Member	55	21-05-18
Adora Ndu BRD	Director/Board Member	43	21-05-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	96,431,770	86,729,303 ( 89.94 %)	222,988 ( 0.2312 %)	89.94 %

Name	Equities	%	Valuation
Venrock Associates 9.644 %	9,300,000	9.644 %	12 M €
BPIFrance Investissement SAS 7.416 %	7,151,863	7.416 %	10 M €
Bpifrance Participations SA /PRIVATE EQUITY/ 7.182 %	6,925,700	7.182 %	9 M €
DBV TECHNOLOGIES 0.1553 %	149,793	0.1553 %	199 247 €
Lyxor International Asset Management SAS 0.1513 %	145,886	0.1513 %	194 050 €
La Française Asset Management SAS 0.0570 %	55,000	0.0570 %	73 158 €
Amundi Asset Management SA (Investment Management) 0.0455 %	43,899	0.0455 %	58 392 €
Don Soland 0.0259 %	25,000	0.0259 %	33 254 €
Michel de Rosen 0.0244 %	23,570	0.0244 %	31 352 €
La Mondiale SAM (Investment Portfolio) 0.0207 %	19,929	0.0207 %	26 509 €

Name	Equities	%	Valuation
Baker Bros. Advisors LP 7.577 %	14,614,264	7.577 %	10 M €
Braidwell LP 4.067 %	7,843,285	4.067 %	5 M €
Yiheng Capital Management LP 2.887 %	5,568,909	2.887 %	4 M €
Point72 Asset Management LP 1.614 %	3,112,500	1.614 %	2 M €
Vivo Capital LLC 1.405 %	2,708,875	1.405 %	2 M €
Threadneedle Asset Management Ltd. 0.5754 %	1,109,719	0.5754 %	764 596 €
Morgan Stanley & Co. International Plc 0.3279 %	632,463	0.3279 %	435 767 €
Millennium Management LLC 0.3033 %	584,886	0.3033 %	402 986 €
Boxer Capital LLC 0.2592 %	500,000	0.2592 %	344 500 €
Pivotal Bioventure Partners Investment Advisor LLC 0.1923 %	370,950	0.1923 %	255 585 €

Name	Equities	%	Valuation
DBV TECHNOLOGIES 0.16%	149,793	0.16%	199,247 $

DBV Technologies SA

177-181, avenue Pierre Brossolette

92120, Montrouge

+33 1 55 42 78 78

http://www.dbv-technologies.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.24 EUR

Average target price

4.733 EUR

Spread / Average Target

+281.72%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
DBV TECHNOLOGIES	-31.75%	129M
MERCK KGAA	+16.10%	79.03B
KYOWA KIRIN CO. LTD.	+8.65%	8.78B
SK BIOPHARMACEUTICALS CO., LTD.	-16.73%	4.83B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+48.34%	4.65B
YUHAN CORPORATION	+2.03%	3.89B
INDIVIOR PLC	+18.57%	2.34B
BETTA PHARMACEUTICALS CO., LTD.	-26.94%	2.18B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.55%	2.11B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-36.25%	2B

Specialty & Advanced Pharmaceuticals